![](https://static.wixstatic.com/media/cd6738_0b608c487611474182c208168c7bc6c3~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_0b608c487611474182c208168c7bc6c3~mv2.webp)
![The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd](https://static.wixstatic.com/media/cd6738_0b608c487611474182c208168c7bc6c3~mv2.jpg/v1/fill/w_269,h_177,fp_0.50_0.50,q_90,enc_auto/cd6738_0b608c487611474182c208168c7bc6c3~mv2.webp)
- Dec 12, 2021
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
![](https://static.wixstatic.com/media/cd6738_14f9fae8c92240c2bd021fd2a8dbc1da~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_14f9fae8c92240c2bd021fd2a8dbc1da~mv2.webp)
![Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM](https://static.wixstatic.com/media/cd6738_14f9fae8c92240c2bd021fd2a8dbc1da~mv2.jpg/v1/fill/w_269,h_178,fp_0.50_0.50,q_90,enc_auto/cd6738_14f9fae8c92240c2bd021fd2a8dbc1da~mv2.webp)
- Dec 11, 2021
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
![](https://static.wixstatic.com/media/cd6738_837cb2b3ab4e4ead8a6b2c1a457eeac1~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_837cb2b3ab4e4ead8a6b2c1a457eeac1~mv2.webp)
![NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2](https://static.wixstatic.com/media/cd6738_837cb2b3ab4e4ead8a6b2c1a457eeac1~mv2.jpeg/v1/fill/w_269,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_837cb2b3ab4e4ead8a6b2c1a457eeac1~mv2.webp)
- Dec 19, 2019
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
![](https://static.wixstatic.com/media/cd6738_baec8a08d8484f8f8793cb304a36e53a~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_baec8a08d8484f8f8793cb304a36e53a~mv2.webp)
![NCT04091126: Phase 1 - Belantamab Mafodotin + Standard of Care New Multiple Myeloma (DREAMM 9) NDMM](https://static.wixstatic.com/media/cd6738_baec8a08d8484f8f8793cb304a36e53a~mv2.jpg/v1/fill/w_269,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_baec8a08d8484f8f8793cb304a36e53a~mv2.webp)
- Dec 13, 2019
NCT04091126: Phase 1 - Belantamab Mafodotin + Standard of Care New Multiple Myeloma (DREAMM 9) NDMM
![](https://static.wixstatic.com/media/cd6738_1e0cf0e2903d4066ad969a02e59ee131~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_1e0cf0e2903d4066ad969a02e59ee131~mv2.webp)
![NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM](https://static.wixstatic.com/media/cd6738_1e0cf0e2903d4066ad969a02e59ee131~mv2.jpeg/v1/fill/w_269,h_181,fp_0.50_0.50,q_90,enc_auto/cd6738_1e0cf0e2903d4066ad969a02e59ee131~mv2.webp)
- Dec 31, 2018
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
![](https://static.wixstatic.com/media/cd6738_84e9e3b8dc39478298e1dd3c6bdf60f1~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_84e9e3b8dc39478298e1dd3c6bdf60f1~mv2.webp)
![NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex](https://static.wixstatic.com/media/cd6738_84e9e3b8dc39478298e1dd3c6bdf60f1~mv2.jpeg/v1/fill/w_269,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_84e9e3b8dc39478298e1dd3c6bdf60f1~mv2.webp)
- Dec 14, 2017
NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex
![](https://static.wixstatic.com/media/cd6738_baf79fe629604b93af7aa16fe02161b5~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_baf79fe629604b93af7aa16fe02161b5~mv2.webp)
![NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM](https://static.wixstatic.com/media/cd6738_baf79fe629604b93af7aa16fe02161b5~mv2.jpeg/v1/fill/w_269,h_179,fp_0.50_0.50,q_90,enc_auto/cd6738_baf79fe629604b93af7aa16fe02161b5~mv2.webp)
- Dec 14, 2017
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
![](https://static.wixstatic.com/media/cd6738_66ece6c8cb1f4bdd8fda94be91037690~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_66ece6c8cb1f4bdd8fda94be91037690~mv2.webp)
![NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)](https://static.wixstatic.com/media/cd6738_66ece6c8cb1f4bdd8fda94be91037690~mv2.jpeg/v1/fill/w_269,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_66ece6c8cb1f4bdd8fda94be91037690~mv2.webp)
- Dec 10, 2017
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
![](https://static.wixstatic.com/media/cd6738_214fe7d3023f447a8de71f9d0b640292~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_214fe7d3023f447a8de71f9d0b640292~mv2.webp)
![NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM](https://static.wixstatic.com/media/cd6738_214fe7d3023f447a8de71f9d0b640292~mv2.jpg/v1/fill/w_269,h_183,fp_0.50_0.50,q_90,enc_auto/cd6738_214fe7d3023f447a8de71f9d0b640292~mv2.webp)
- Dec 5, 2017
NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM
![](https://static.wixstatic.com/media/cd6738_f9ad3901492045fab1e4914554f35bb3~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_f9ad3901492045fab1e4914554f35bb3~mv2.webp)
![NCT03224507: Phase 2 - Monoclonal Antibody-Based Sequential Therapy for Deep Remission in MM -MASTER](https://static.wixstatic.com/media/cd6738_f9ad3901492045fab1e4914554f35bb3~mv2.jpg/v1/fill/w_269,h_177,fp_0.50_0.50,q_90,enc_auto/cd6738_f9ad3901492045fab1e4914554f35bb3~mv2.webp)
- Dec 1, 2017
NCT03224507: Phase 2 - Monoclonal Antibody-Based Sequential Therapy for Deep Remission in MM -MASTER
![](https://static.wixstatic.com/media/cd6738_e7fcd249bd41483dab217274ec4eb3b8~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_e7fcd249bd41483dab217274ec4eb3b8~mv2.webp)
![NCT02203643: Phase 2 - Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex - NDMM - FORTE](https://static.wixstatic.com/media/cd6738_e7fcd249bd41483dab217274ec4eb3b8~mv2.jpeg/v1/fill/w_269,h_183,fp_0.50_0.50,q_90,enc_auto/cd6738_e7fcd249bd41483dab217274ec4eb3b8~mv2.webp)
- Dec 6, 2014
NCT02203643: Phase 2 - Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex - NDMM - FORTE